Latest News

Anti-Cancer Agents & Biologic Therapy - Breast Cancer, Metastatic

BELLE-3 Results Do Not Support Further Buparlisib–Fulvestrant Development

  • 11 Dec 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Safety findings rule out buparlisib plus fulvestrant for postmenopausal, hormone receptor-positive, HER2-negative breast cancer that has progressed after endocrine therapy and mTOR inhibition...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof BELLE-3 Results Do Not Support Further Buparlisib–Fulvestrant Development

Cancer Immunology and Immunotherapy - Urothelial Cancers

JAVELIN Points To Further Avelumab Investigation For Metastatic Urothelial Carcinoma

  • 08 Dec 2017

Avelumab shows tolerability and efficacy in patients with metastatic urothelial carcinoma that has progressed after platinum-based chemotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof JAVELIN Points To Further Avelumab Investigation For Metastatic Urothelial Carcinoma

Cancer Immunology and Immunotherapy - Geriatric Oncology - Melanoma and other Skin Tumours

Metastatic Melanoma Immunotherapy Response May Be Linked To Age

  • 07 Dec 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Older age could be a positive prognostic factor for metastatic melanoma patients using immunotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Metastatic Melanoma Immunotherapy Response May Be Linked To Age

PD-L1 in Cancer: ESMO Biomarker Factsheet

Factsheets on biomarkers prepared by Hendrik Tobias Arkenau with statements on prognostic and predictive value, testing recommendations, and more.

 

view detailsof

Anti-Cancer Agents & Biologic Therapy - Non-Small-Cell Lung Cancer, Metastatic - Personalised Medicine

Osimertinib Shows Potential For TKI-Refractory NSCLC With Leptomeningeal Metastases

  • 06 Dec 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Preliminary results suggest that osimertinib might be feasible for the treatment of TKI-refractory leptomeningeal metastases in non-small-cell lung cancer patients with the T790M mutation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Osimertinib Shows Potential For TKI-Refractory NSCLC With Leptomeningeal Metastases

Cancer Immunology and Immunotherapy - AIDS-Associated Malignancies - Non-Small-Cell Lung Cancer, Metastatic

NSCLC Nivolumab Case Study Reports HIV Reservoir Depletion

  • 05 Dec 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

HIV reservoir depletion reported after immune checkpoint inhibitor therapy in an HIV-positive patient with non-small-cell lung cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof NSCLC Nivolumab Case Study Reports HIV Reservoir Depletion

Anti-Cancer Agents & Biologic Therapy - Hepatobiliary Cancers

Gemcitabine–Platinum Chemotherapy Regimen Potential For Hepatocholangiocarcinoma

  • 04 Dec 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Advanced hepatocholangiocarcinoma may be sensitive to chemotherapy containing platinum agents and gemcitabine...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Gemcitabine–Platinum Chemotherapy Regimen Potential For Hepatocholangiocarcinoma

Anti-Cancer Agents & Biologic Therapy - Urothelial Cancers - Surgery and/or Radiotherapy of Cancer

Adjuvant Chemotherapy Plus Radiotherapy Benefits Reported For Locally Advanced Bladder Cancer

  • 01 Dec 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients undergoing chemotherapy after radical cystectomy for locally advanced bladder cancer may experience improved locoregional recurrence-free survival with the addition of radiotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Adjuvant Chemotherapy Plus Radiotherapy Benefits Reported For Locally Advanced Bladder Cancer

Anti-Cancer Agents & Biologic Therapy - Personalised Medicine

Vemurafenib Achieves ‘Prolonged Efficacy’ For BRAF-Mutated Erdheim–Chester Disease

  • 30 Nov 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Final analysis of the VE-BASKET trial suggests long-term survival benefit for vemurafenib in select patients with Erdheim–Chester disease or Langerhans cell histiocytosis...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Vemurafenib Achieves ‘Prolonged Efficacy’ For BRAF-Mutated Erdheim–Chester Disease

Oesophageal Cancer - Surgery and/or Radiotherapy of Cancer

HRQoL Outcomes Support CROSS Neoadjuvant Chemoradiotherapy Benefits

  • 29 Nov 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Health-related quality of life after surgery for locally advanced oesophageal or gastro-oesophageal junction cancer is not adversely affected by use of neoadjuvant chemoradiotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof HRQoL Outcomes Support CROSS Neoadjuvant Chemoradiotherapy Benefits

Head and Neck Cancers

Progressive Neurocognitive Decline Observed In Radiotherapy-Treated HNSCC Patients

  • 28 Nov 2017
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Head and neck cancer patients remain at risk of long-term neurocognitive deficits after undergoing definitive radiotherapy or chemoradiotherapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Progressive Neurocognitive Decline Observed In Radiotherapy-Treated HNSCC Patients

Anti-Cancer Agents & Biologic Therapy - Breast Cancer, Early Stage

Neoadjuvant HER2 Blockade Plus Systemic Chemotherapy Best For Achieving Breast Cancer pCR

  • 27 Nov 2017
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

The use of neoadjuvant trastuzumab emtansine instead of docetaxel, carboplatin and trastuzumab, both given alongside pertuzumab, is not supported for patients with stage II–III HER2-positive breast cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Neoadjuvant HER2 Blockade Plus Systemic Chemotherapy Best For Achieving Breast Cancer pCR

Anti-Cancer Agents & Biologic Therapy - Breast Cancer, Early Stage

Intermittent Regimen ‘Feasible’ For Adjuvant Letrozole

  • 22 Nov 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Extending adjuvant endocrine therapy with letrozole achieves similar disease-free survival whether given continuously or on an intermittent schedule...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Intermittent Regimen ‘Feasible’ For Adjuvant Letrozole

Anti-Cancer Agents & Biologic Therapy - Central Nervous System Malignancies

Bevaciziumab Fails To Boost OS For Progressive Glioblastoma

  • 20 Nov 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Adding bevacizumab to lomustine does not improve overall survival for patients with glioblastoma that has progressed after chemoradiation...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Bevaciziumab Fails To Boost OS For Progressive Glioblastoma

Cancer Immunology and Immunotherapy - Cervical Cancer

Ipilimumab Fails To Demonstrate Clinical Activity For Advanced Cervical Cancer

  • 20 Nov 2017
  • Author : By Lynda Williams, Senior medwireNews Reporter

Ipilimumab did not show significant single-agent activity in patients with human papillomavirus-related recurrent or metastatic cervical cancer...

ESMO members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Ipilimumab Fails To Demonstrate Clinical Activity For Advanced Cervical Cancer